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Introduction
Severe congenital neutropenia is a heterogeneous group of in-
herited  disorders  characterized  by  neutropenia  and  recurrent 
bacterial infections. Kostmann disease is an autosomal reces-
sive form of severe congenital neutropenia caused by loss-of-
function point mutations in the HAX1 gene (Klein et al., 2006). 
HS1-associated protein X-1 (Hax1) was first identified as a 
binding partner of the hematopoietic-specific cortactin homo-
logue HS1 (Suzuki et al., 1997) and has been implicated in reg-
ulating the actin cytoskeleton and apoptosis. Although it has 
also been proposed that loss of Hax1 results in neutropenia by 
affecting neutrophil apoptosis (Klein et al., 2006), a recent study 
has challenged this role (Jeyaraju et al., 2009).
Hax1 is a ubiquitous protein that regulates the actin cyto-
skeleton and migration of cancer cells. Hax1 interacts directly 
with  adhesion  and  cytoskeletal  proteins,  including  cortactin, 
HS1, G13, and 6 integrins. Depletion of endogenous Hax1 
using  siRNA  impairs  v6  integrin–mediated  migration  of 
squamous cell carcinoma (Ramsay et al., 2007) and reduces   
migration of NIH3T3 cells (Radhika et al., 2004). However, no 
previous studies have addressed how Hax1 modulates neutrophil 
motility. Here, we characterize how Hax1 regulates neutrophil 
chemotaxis using small hairpin RNA (shRNA) depletion and 
live imaging with microfluidic gradient generators. We identi-
fied a new role for Hax1 as a regulator of neutrophil uropod   
detachment and chemotaxis through the modulation of integrin-
mediated adhesion and Rho GTPase signaling.
Results and discussion
Hax1 localizes to the leading edge during 
chemotaxis, and its expression is regulated 
by neutrophil differentiation
Hax1 is a ubiquitously expressed protein that directly interacts 
with HS1, G13, and integrin 6 at its C terminus (Fig. 1 A; 
Suzuki et al., 1997; Radhika et al., 2004; Ramsay et al., 2007). 
To characterize Hax1 expression and localization in neutrophils, 
we used the myeloid leukemia cell line PLB-985, which can be 
terminally differentiated into neutrophil-like cells (Tucker et al., 
1987). To determine whether Hax1 expression is regulated by 
differentiation, we used immunoblotting to detect endogenous 
Hax1. Surprisingly, we observed a reduction in Hax1 expression   
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display increased neutrophil apoptosis in response to TNF- 
or H2O2 (Klein et al., 2006). In the presence of H2O2, we ob-
served a mild increase in the apoptosis of Hax1-deficient cells 
compared with control cells by annexin V staining, suggesting 
that Hax1 may modulate the sensitivity of PLB-985 cells to 
proapoptotic stimuli. However, there was no increase in the 
basal level of apoptosis (Fig. S1 A). Although Hax1 expression 
is regulated by neutrophil differentiation, we did not observe 
a defect in the differentiation of Hax1-depleted PLB-985 cells 
as indicated by normal surface expression of M2 integrin 
(Fig. S1 B).
To determine whether Hax1 is necessary for neutrophil 
chemotaxis, we performed time-lapse imaging of PLB-985 cells 
responding  to  a  gradient  of  N-formyl-l-methionyl-l-leucyl- 
l-phenylalanine (fMLP) supplied from a micropipette tip. 
Hax1-deficient cells displayed impaired motility and an elon-
gated uropod during chemotaxis on fibrinogen (Fig. 2, B and C; 
and Videos 4 and 5). Quantification of uropod length showed 
a greater than twofold increase in both Hax1-deficient cell lines 
compared with control (Fig. 2 C). The abnormal uropod mor-
phology and detachment phenotype are similar to what has been 
reported with Rho inhibition (Alblas et al., 2001; Worthylake 
and Burridge, 2001; Yoshinaga-Ohara et al., 2002), suggesting 
that Hax1 may modulate rear retraction by regulating Rho 
GTPase signaling.
To determine whether Hax1 regulates Rho GTPase activa-
tion, RhoA activity assays were performed in control and Hax1-
deficient cell lines. Using a pull-down assay, we found that 
RhoA activation was significantly decreased in Hax1-deficient 
PLB-985  cells  stimulated  with  fMLP  either  in  suspension   
(Fig. S1 C) or adherent to fibrinogen (Fig. 2 D). No significant 
difference in RhoA activity was detected in the absence of fMLP 
(unpublished data). Quantification of RhoA-GTP demonstrated 
in differentiated PLB-985 cells induced with DMSO compared 
with undifferentiated cells (Fig. 1 B). This is in contrast to vin-
culin, HS1, and actin, which were all increased upon differenti-
ation. This finding suggests that Hax1 expression may play a 
role during neutrophil differentiation.
To characterize the intracellular distribution of Hax1 dur-
ing neutrophil chemotaxis, we examined the subcellular local-
ization of Hax1 in PLB-985 cells. We coexpressed Hax1-GFP 
and a marker of the neutrophil uropod that binds to stable F-actin, 
utrophin-RFP, in PLB-985 cells (Fig. 1 C and Videos 1, 2, and 3; 
Burkel et al., 2007; Cooper et al., 2008; Yoo et al., 2010). Live 
imaging demonstrated that Hax1-GFP predominantly localized 
to the leading edge, although rearward localization was also 
noted. To characterize the determinants of Hax1 localization, 
we generated truncation constructs lacking the C-terminal 166 
amino  acids  necessary  for  binding  HS1  and  G13.  Hax1   
1–113–GFP no longer showed leading edge localization and 
concentrated in the middle of the cell body (Fig. 1 C and Video 2). 
In contrast, Hax1113-GFP, which lacks the N-terminal 113 
amino acids, was sufficient to localize to the leading edge of 
PLB-985 cells (Fig. 1 C and Video 3).
An attractive interacting partner that may mediate this tar-
geting is the actin-binding protein HS1, which stabilizes actin 
branching at the leading edge (Uruno et al., 2003; Hao et al., 
2005). Collectively, our findings identify Hax1 as a leading edge 
component that is differentially expressed during the differenti-
ation of neutrophil-like PLB-985 cells.
Hax1 is necessary for neutrophil  
uropod detachment
To characterize Hax1 function, Hax1-deficient PLB-985 cells 
were generated using lentiviral-mediated shRNA (Fig. 2 A). 
Kostmann disease patients with loss-of-function Hax1 mutations 
Figure 1.  Hax1 expression in PLB-985 cells and localization during chemotaxis. (A) Schematic of Hax1 modified from (Jeyaraju et al., 2009). Bind-
ing sites for HS1 (Suzuki et al., 1997), G13 (Radhika et al., 2004), and 6 integrin (Ramsay et al., 2007) are shown. Hax1-GFP constructs are 
used in C. (B) Hax1 expression is decreased upon differentiation. Vinculin, HS1, and actin were included as controls and show increased expression 
with neutrophil differentiation. Quantification of expression represents the ratio of differentiated to undifferentiated cells as mean intensity ± SDs 
from three independent experiments as described in Materials and methods. (C) Still image from time-lapse videos of utrophin-RFP and Hax1-GFP 
localization in PLB-985 cells. Utrophin-RFP was coexpressed with full-length Hax1-GFP (Video 1), Hax1 1–113–GFP (Video 2), and Hax1113-GFP 
(Video 3) in differentiated PLB-985 cells and then imaged during chemotaxis on 10 µg/ml fibrinogen in response to a needle containing 1 µM fMLP. 
Bar, 10 µm.467 Hax1 negatively regulates neutrophil adhesion • Cavnar et al.
localization of utrophin in neutrophils migrating in vivo (Yoo 
et al., 2010). We also found that Y-27632 impaired the uro-
pod localization of utrophin-GFP (Fig. 2, E and F; and Video 6). 
To determine whether Hax1 affects the uropod localization 
of utrophin, we expressed utrophin-GFP in control and Hax1-
deficient  cells  and  performed  time-lapse  imaging  during 
neutrophil  chemotaxis. The  ratio  of  fluorescence  intensity 
from the front of the cell to the rear showed a significant   
reduction of utrophin-GFP at the uropod of Hax1-deficient 
cells compared with control cells during chemotaxis (Fig. 2, 
E and F; and Video 7). Collectively, our findings suggest that 
a >10-fold reduction in RhoA activity in Hax1-deficient cells 
(Fig. 2 D). In contrast, Rac activation was increased approxi-
mately twofold in Hax1 knockdown cells (Fig. S1 D). Collec-
tively, our findings indicate that Hax1 expression is necessary 
for optimal RhoA activity in neutrophils.
To  determine  whether  Hax1  modulates  the  localized 
polarity of F-actin dynamics in motile neutrophils, we exam-
ined the localization of a probe for stable F-actin, utrophin-
GFP, in control and Hax1-deficient PLB-985 cells. In previous 
experiments, we have reported that inhibition of the Rho- 
associated protein kinase with Y-27632 perturbs the uropod 
Figure 2.  Hax1 depletion impairs uropod retraction and reduces RhoA activation. (A) Lentiviral knockdown of Hax1 (Hax1 shRNA A and B) in PLB-985 
cells display significant depletion of Hax1 compared with control shRNA. Quantification was normalized to vinculin loading control. ***, P < 0.01; 
ANOVA with Tukey posttest. (B) Still image from a time-lapse video of control shRNA and Hax1 shRNA A and B PLB-985 cells during chemotaxis on   
10 µg/ml fibrinogen (Videos 4 and 5). Arrowheads indicate elongated uropods of Hax1-deficient PLB-985 cells during chemotaxis. Bar, 100 µm. (C) Quantifi-
cation of uropod length in Hax1-deficient cells compared with control. Control shRNA (n = 279) cells, Hax1 shRNA A (n = 275) cells, and Hax1 shRNA B 
(n = 241) cells were from three independent experiments. The graph represents means ± 95% confidence interval. ***, P < 0.01; one-way ANOVA with 
Tukey posttest. (D) GST-RBD pull-down assays show a 10-fold decrease in RhoA activity in Hax1-deficient cells compared with control. ***, P < 0.01; t test. 
(E) Control and Hax1-deficient PLB-985 cells expressing utrophin-GFP during chemotaxis to 1 µM fMLP on fibrinogen (Videos 6 and 7). For Rho-associated 
protein kinase inhibition, cells were incubated with 30 µM Y-27632 for 30 min before imaging. Fluorescence intensity from the front to the back of the cell 
was determined by line scan analysis (yellow lines). Bar, 10 µm. (F) Quantification of line scan analysis of utrophin-GFP localization from E. P-values were 
obtained by ANOVA with Tukey posttest. Red lines indicate the mean fluorescence ratio from three independent experiments. Error bars are means ± SEM 
from three independent experiments. A.U., arbitrary unit.JCB • VOLUME 193 • NUMBER 3 • 2011   468
flow free conditions and can be used successfully to study neu-
trophil chemotaxis in a high throughput format (Abhyankar   
et al., 2008; Berthier et al., 2010). Hax1-deficient PLB-985 cells 
displayed impaired chemotaxis with a uropod retraction defect in 
a linear gradient of fMLP on fibrinogen, in accordance with our 
findings using the micropipette assay (Fig. 3, A and B; and   
Videos 8 and 9). Quantification by cell tracking revealed a signifi-
cantly decreased velocity of Hax1-deficient cells compared with 
control cells on all ligands tested (Fig. 3, C and D). Interestingly, 
directionality was not impaired in Hax1 knockdown cells, sug-
gesting that directional sensing is intact (Fig. 3 C, insets).
Hax1 regulates the polarity of F-actin dynamics and rear de-
tachment, likely through RhoA.
Inhibition of integrin-mediated  
adhesion rescues chemotaxis of  
Hax1-deficient neutrophils
To further characterize how Hax1 regulates neutrophil motility 
and uropod detachment, live imaging of control and Hax1- 
deficient cells was performed in microfluidic gradient generators. 
Static microfluidic gradient generation allows the precise con-
trol of chemoattractant gradients over extended durations under 
Figure 3.  Directed migration is impaired in Hax1-deficient PLB-985 cells using microfluidic gradient generators. (A) Schematic of the microfluidic device 
showing stable gradient formation with Alexa Fluor 488–conjugated dextran quantified by line scan analysis (yellow line). C/Csource, concentration of the 
line scan over concentration of the source. (B) Image taken from a time-lapse video of control and Hax1 knockdown cells during chemotaxis on fibrinogen 
(Videos 8 and 9). Hax1-deficient cells display impaired migration and develop elongated tails (arrowheads). Insets are zoomed regions indicated by the 
white squares. Bar, 100 µm. (C) Representative velocity and angle (insets) histogram of control and Hax1-deficient cells during chemotaxis on fibrinogen 
in the absence and presence of 2 or v3 integrin function-blocking antibodies (from one of three independent experiments; n = 10 cells tracked over 
30 min during chemotaxis). (D) Mean velocity heat map from three independent experiments in triplicate of control and Hax1 knockdown cells during 
chemotaxis on fibronectin (Fn), fibrinogen (Fbg), and vitronectin (Vn) and in the presence of integrin function-blocking antibodies on fibrinogen. n = 30 cells   
per replicate. ***, P < 0.01; t test.469 Hax1 negatively regulates neutrophil adhesion • Cavnar et al.
M2 integrin (CD11b) in Hax1-deficient PLB-985 cells com-
pared with control cells (Fig. S1 B and Fig. S2 C). To determine 
whether the increased adhesion observed in Hax1-deficient 
cells was mediated by cell surface integrins, we characterized 
the effects of 2 and v3 integrin function-blocking antibodies 
on the adhesion of control and Hax1 knockdown cells. Inhibi-
tion of either 2 or v3 integrins reduced the maximum adhe-
sion observed (Fig. 4 B), whereas control IgG antibody had no 
effect (not depicted).
To further investigate the relationship between Hax1 and 
RhoA in the regulation of neutrophil adhesion and motility, 
RNA interference was used to deplete RhoA from PLB-985 
cells (Fig. 4 C). Similar to Hax1 depletion, RhoA-deficient neu-
trophils displayed a significant increase in adhesion to fibrino-
gen (Fig. 4 D). Under steep gradients of fMLP using the 
needle assay, RhoA-deficient neutrophils exhibited impaired 
migration with multiple protrusions, similar to what has been 
previously reported (Video 10; Heasman et al., 2010). In micro-
fluidic chambers that produce shallow chemoattractant gra-
dients,  RhoA  knockdown  cells  showed  impaired  migration 
with elongated uropods and impaired detachment, similar to 
Hax1-deficient cells (Fig. 4 E and Fig. S2 D). Collectively, our 
To determine whether increased neutrophil-mediated adhe-
sion was responsible for the impaired migration of Hax1-deficient 
cells, we characterized the effects of 2 and v3 integrin 
function-blocking antibodies on the directed migration of Hax1 
knockdown cells. Both antibody treatments increased the mi-
gration velocity of Hax1-deficient cells to control levels on fi-
brinogen (Fig. 3, B–D), whereas control IgG antibody had no 
effect (not depicted), indicating that the impaired migration was 
caused, at least in part, by increased integrin-mediated adhe-
sion. Collectively, our findings demonstrate that Hax1 is neces-
sary for efficient neutrophil chemotaxis on different integrin 
ligands by modulating uropod retraction.
Hax1 and RhoA regulate neutrophil 
adhesion and motility
To determine whether Hax1 regulates global neutrophil adhe-
sion, adhesion of control and Hax1-deficient cells was quanti-
fied on different ligands. Hax1-deficient PLB-985 cells treated 
with fMLP displayed a more than twofold increase in adhesion 
compared with control cells (Fig. 4 A), which was dependent on 
ligand density (Fig. S2, A and B). We did not observe differences 
in the surface expression of v3 integrin, total 2 integrin, or 
Figure 4.  Hax1- and RhoA-deficient PLB-985 cells display increased integrin-mediated adhesion. (A) Adhesion assay of differentiated control and Hax1-
deficient cells on fibronectin (Fn), fibrinogen (Fbg), and vitronectin (Vn). (B) Adhesion assay of control and Hax1-deficient cells on 10 µg/ml fibrinogen. 
For antibody blocking, cells were incubated with 2 or v3 integrin function-blocking antibodies as described in Materials and methods. (C) Lentiviral 
knockdown of RhoA in PLB-985 cells. (D) Adhesion assay of differentiated control and RhoA-deficient PLB-985 cells on 10 µg/ml fibrinogen. (E) Migration 
velocities of differentiated control and RhoA-deficient cells during chemotaxis in microfluidic gradient generators. P-values were obtained by ANOVA with 
Tukey posttest (control shRNA, n = 23 cells and RhoA shRNA 1 and RhoA shRNA 2, n = 22 cells; horizontal lines indicate the mean velocity from three 
independent experiments). *, P < 0.05. Error bars indicate means ± SEM from three independent experiments.JCB • VOLUME 193 • NUMBER 3 • 2011   470
interacting partners that bind to the N-terminal 113 amino acids 
of Hax1.
Constitutively active RhoA rescues 
adhesion and partially rescues motility of 
Hax1-deficient neutrophils
To determine whether activation of RhoA is sufficient to rescue 
the adhesion and motility defects of Hax1-deficient neutrophils, 
we treated control and Hax1-depleted cells with nocodazole and 
colchicine or ectopically expressed constitutively active RhoA 
(Q63L). It has previously been reported that microtubule dis-
ruption with either nocodazole or colchicine increases global 
Rho activity in neutrophils (Niggli, 2003; Xu et al., 2005).   
Accordingly, we found that treatment with either nocodazole or 
colchicine rescued the adhesion defect of fMLP-treated Hax1-
deficient cells to control levels (Fig. 5 B and Fig. S3 C). Moreover, 
findings demonstrate that Hax1 and RhoA regulate neutrophil 
chemotaxis through the modulation of integrin-mediated adhe-
sion and uropod detachment.
The N-terminal region of Hax1 is sufficient 
to rescue neutrophil adhesion and motility 
of Hax1-deficient cells
We next sought to identify the regions of Hax1 that are sufficient 
to rescue the adhesion and motility defects of Hax1-deficient cells. 
Stable  expression  of  shRNA-resistant  full-length  GFP-Hax1 
(Fig. S3 A) was sufficient to rescue both neutrophil adhesion 
and chemotaxis (Fig. 5, A and D). Hax1-deficient PLB-985 
cells stably expressing the N-terminal 113 amino acids of Hax1 
(GFP–Hax1 1–113), but not the C-terminal 166 amino acids 
(GFP-Hax1113),  rescued  neutrophil  adhesion  and  motility 
(Fig. 5, A and D). Interestingly, there are currently no known 
Figure 5.  Constitutively active RhoA and the N-terminal region of Hax1 rescue neutrophil adhesion. (A) Adhesion assays of control cells stably expressing 
GFP and Hax1 shRNA A cells expressing GFP, or an shRNA-resistant GFP-Hax1, GFP–Hax1 1–113, and GFP-Hax1113 were plated on 10 µg/ml fibrino-
gen in the presence or absence of 200 nM fMLP. (B) Adhesion assay of control and Hax1-deficient cells plated on 10 µg/ml fibrinogen in the presence or 
absence of 200 nM fMLP and 10 µM colchicine for 30 min. (C) Adhesion assay of control and Hax1-deficient cells stably expressing GFP or GFP-RhoA 
(Q63L). (B and C) ***, P < 0.01; one-way ANOVA with Tukey posttest. (D) Migration velocities of control and Hax1-deficient cells stably expressing GFP, 
GFP-RhoA (Q63L), GFP-Hax1, GFP–Hax1 1–113, and GFP-Hax1113 during chemotaxis to fMLP in microfluidic chemotaxis devices. Horizontal lines 
indicate the mean velocity. (A and D) Means with common letters indicate P > 0.05 by ANOVA with Tukey posttest.471 Hax1 negatively regulates neutrophil adhesion • Cavnar et al.
migration may be key factors that contribute to the pathogenesis 
of other congenital neutropenia syndromes, such as Kostmann dis-
ease. A challenge for future studies will be to establish in vivo sys-
tems that will allow these kinds of questions to be answered.
Materials and methods
Antibodies and reagents
Sources for antibodies and reagents used in this study are mouse anti-Hax1 
clone 52 and mouse anti-HS1 clone 9 (BD), rabbit anti-Hax1 (Proteintech 
Group, Inc.), mouse antivinculin clone VIN-11-5 and mouse anti–-actin 
clone  AC-15  (Sigma-Aldrich),  rabbit  anti-RhoA  (67B9)  and  rabbit  anti-
Rac1/2/3 (L129; Cell Signaling Technology), goat anti–rabbit Alexa Fluor 
680 and goat anti–mouse Alexa Fluor 800 (Invitrogen), and mouse anti–
v3 integrin (clone LM609; Millipore), mouse anti–human CD18 (clone 
TS1/18), and mouse anti–human Cd11b (clone CBRM1/5; BioLegend). 
Human fibrinogen, f-Met-Leu-Phe (Sigma-Aldrich), nocodazole (EMD), col-
chicine (Arcos Organics), and fibronectin were purified from human plasma 
by  affinity  chromatography  as  previously  described  (Ruoslahti  et  al., 
1982), and human vitronectin was a gift from D. Mosher (University of 
Wisconsin–Madison, Madison, WI).
Cell culture
PLB-985 cells (gift from C. Parent, National Cancer Institute, National Insti-
tutes of Health, Bethesda, MD) were maintained in RPMI 1640 supple-
mented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml 
streptomycin at a concentration of 0.1–1 × 10
6 cells/ml. To differentiate, 
1.25% DMSO was added to 2 × 10
5 cells/ml for 6 d. Differentiation was 
confirmed through FACS analysis of CD11b expression. HEK293T cells 
(American Type Culture Collection) and Platinum-GP cells (Cell Biolabs, Inc.) 
were maintained in Dulbecco’s minimal essential medium supplemented 
with 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin.
DNA constructs, transfections, and viral infections
Hax1  was  RT-PCR  purified  from  TRIZOL-extracted  total  RNA  from  the 
neutrophil-like cell line HL-60 using the primers forward, 5-ATGAGCC-
TCTTTGATCTCTTCCGGGGCTTTTTCG-3, and reverse, 5-CCGGGACC-
GGAACCAACGTCCCAGGAATAAGT-3. Full-length Hax1, Hax1 1–113, 
and Hax1113 sequences were PCR amplified from Hax1 cDNA and 
cloned into pEGFP-N1 and pEGFP-C1 (Takara Bio Inc.). 2 × 10
6 PLB-985 
cells 6 d after differentiation were transiently transfected with 5 µg DNA 
using a nucleofector (Cell Line Nucleofector Kit V; Lonza) following the 
manufacturer’s instructions.
Lentiviral  Hax1  and  RhoA  shRNA  targets  were  purchased  from 
Thermo Fisher Scientific. Targets used in this study were Hax1 shRNA A, 
5-ACAGACACTTCGGGACTCAAT-3; Hax1 shRNA B, 5-CCAGAGGCCA-
TTTCATAGGTT-3; RhoA shRNA 1, 5-GTACATGGAGTGTTCAGCAAA-3;   
RhoA shRNA 2, 5-TGGAAAGACATGCTTGCTCAT-3; and control shRNA, 
5-TGTCTCCGAACGTGTCACGTT-3. HEK293T cells were grown to 70% 
confluency in a 10-cm tissue-culture dish for each lentiviral target and trans-
fected using 6 µg Hax1 or RhoA shRNA, 0.6 µg VSV-G, and 5.4 µg CMV 
8.9.1. A 72-h viral supernatant was collected and concentrated using a 
lentivirus concentrator (Lenti-X; Takara Bio Inc.) following the manufacturer’s in-
structions. 10
6 PLB-985 cells were infected with viral supernatant for 3 d in 
the presence of 4 µg/ml polybrene. Stable cell lines were generated with 
1 µg/ml puromycin selection.
Retroviral  transduction  of  GFP-RhoA  (Q63L)  and  shRNA-resistant 
GFP-Hax1, GFP–Hax1 1–113, and GFP-Hax1113 was performed as fol-
lows: Platinum-GP cells were grown to 70% confluency in a 10-cm tissue-
culture dish and transfected using 10 µg retroviral DNA and 3 µg VSV-G. 
A 72-h viral supernatant was collected and added to 10
6 PLB-985 cells for 
3 d in the presence of 15 µg/ml polybrene. Cells were sorted for equal 
GFP expression levels using the cell sorter (FACSAria; BD) at the University 
of Wisconsin flow cytometry facility.
Needle chemotaxis
Stable cell lines expressing shRNA cell lines or transiently transfected cells 
expressing GFP or RFP fusion proteins were incubated in a 35-mm glass-
bottom culture dish that had been coated with 10 µg/ml fibrinogen and 
blocked with 2% BSA. 10
6 neutrophils were placed in Gey’s media (20 mM 
Hepes, 132 mM NaCl, 1 mM MgSO4, 1.2 mM NaH2PO4, 5 mM glucose, 
1 mM CaCl2, and 0.5% human serum albumin; American Red Cross Blood 
Services), and chemotaxis assays were performed using a microinjection 
stable expression of constitutively active GFP-RhoA (Q63L) 
(Fig. S3 B) in Hax1-deficient cells restored adhesion to control 
levels (Fig. 5 C). We did not observe any decrease in endog-
enous RhoA or Rac expression in PLB-985 cells that ectopically 
express constitutively active GFP-RhoA (Q63L) as has previ-
ously been reported for other cell types (Fig. S3 B; Boulter et al., 
2010). Ectopic expression of constitutively active RhoA only 
partially rescued the migration defect of Hax1-deficient cells, 
suggesting that Hax1 may be necessary for optimum spatiotem-
poral regulation of RhoA during motility (Fig. 5 D). Collectively, 
our findings demonstrate that activation of RhoA is sufficient to 
rescue the adhesion defect of Hax1-deficient cells, indicating 
that Hax1 negatively regulates neutrophil adhesion through the 
modulation of RhoA activity.
In summary, we have identified Hax1 as a novel negative 
regulator of integrin-mediated adhesion that affects uropod de-
tachment and neutrophil chemotaxis. We have also found that 
Hax1 regulates RhoA activation in neutrophils and that activa-
tion of RhoA is sufficient to rescue the adhesion defects of 
Hax1-deficient cells. Previous studies have suggested that Hax1 
loss-of-function mutations mediate the development of congen-
ital neutropenia syndromes through the regulation of neutrophil 
apoptosis (Klein et al., 2006; Chao et al., 2008). Our findings 
raise the intriguing alternative hypothesis that Hax1 deficiency 
may modulate neutrophil function by affecting Rho GTPase 
signaling and neutrophil adhesion and motility.
It is not clear how Hax1 regulates RhoA activity and neu-
trophil adhesion. G13 and HS1 represent attractive candidates 
to mediate Hax1 effects. However, we found that the N-terminal 
region of Hax1, but not the region that interacts with G13 and 
HS1, is sufficient to rescue neutrophil adhesion and motility. 
Accordingly, the C-terminal region of Hax1 localizes to the 
leading edge, whereas the N-terminal region of Hax1, which 
rescues uropod retraction, displays a more rearward localiza-
tion. Furthermore, we found that ectopic expression of Hax1 
and constitutively active RhoA (Q63L) was sufficient to restore 
the increased adhesion defect in Hax1-deficient cells. Interest-
ingly, RhoA (Q63L) only partially rescued neutrophil motility, 
suggesting that the proper spatiotemporal regulation of RhoA is 
critical for efficient chemotaxis. To date, no binding partners 
have been identified that interact with the N-terminal region of 
Hax1. Understanding these types of interactions will likely shed 
light on how Hax1 functions to regulate rear detachment and 
neutrophil motility.
A final unanswered question is how Hax1 mutations affect 
neutrophil adhesion and motility to control neutrophil homeo-
stasis in the context of congenital neutropenia syndromes. The 
finding that Hax1 expression is reduced with neutrophil differ-
entiation is surprising. This raises the intriguing possibility that 
Hax1 expression has an important function during neutrophil 
differentiation and that its deficiency may allow the transition to 
the more adherent phenotype of mature neutrophils. Recent studies 
have shown that other congenital neutropenia syndromes, includ-
ing WHIM (warts, hypogammaglobulinemia, infections, and 
myelokathexis) syndrome, have associated defects in neutro-
phil retention and motility (Kawai and Malech, 2009; Walters   
et al., 2010), suggesting that defects in neutrophil adhesion and JCB • VOLUME 193 • NUMBER 3 • 2011   472
LM609, which binds to the v3 complex, anti-CD18, or anti-CD11b for 
30 min on ice. Cells were washed twice with FACS buffer (PBS supple-
mented with 2% FBS and 0.02% NaN3) and analyzed by flow cytometry. 
For apoptosis induction of PLB-985 cells, 10
5 5-d differentiated cells were 
incubated with 1 mM H2O2 for 30 min in PLB-985 media and then incu-
bated in fresh media for 12 h. Cells were analyzed for apoptosis induction 
using the Annexin V Apoptosis Detection kit I (BD) following the manufac-
turer’s instruction and analyzed by flow cytometry.
Statistical analysis
For statistical comparison, unpaired t test or one-way analysis of vari-
ance (ANOVA) was used with Tukey posttests with P < 0.05 consid-
ered significant.
Online supplemental material
Fig. S1 shows that Hax1-deficient PLB-985 cells have increased sensitivity 
to H2O2-induced apoptosis, reduced RhoA-GTP, and increased Rac-GTP 
levels. Fig. S2 shows that Hax1-deficient PLB-985 cells have increased 
adhesion to vitronectin and fibrinogen, and RhoA-deficient cells display 
elongated uropods. Fig. S3 shows immunoblotting of Hax1-deficient PLB-
985 cells expressing GFP-Hax1, Hax1 mutants, and constitutively active 
RhoA (Q63L). Video 1 shows Hax1-GFP localization in PLB-985 cells 
during chemotaxis. Video 2 shows Hax1 1–113–GFP localization in PLB-
985 cells during chemotaxis. Video 3 shows Hax1113-GFP localization 
in PLB-985 cells during chemotaxis. Video 4 shows the chemotaxis of con-
trol shRNA PLB-985 cells. Video 5 shows the chemotaxis of Hax1 shRNA 
A PLB-985 cells. Video 6 shows utrophin-GFP localization in PLB-985 cells 
treated  with  Y-27632  during  chemotaxis.  Video  7  shows  utrophin-GFP 
localization in Hax1 shRNA A–expressing PLB-985 cells during chemo-
taxis. Video 8 shows control shRNA chemotaxis in microfluidic gradient 
generators.  Video  9  shows  Hax1  shRNA  A  chemotaxis  in  microfluidic 
gradient generators. Video 10 shows RhoA-deficient PLB-985 cells during 
chemotaxis. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.201010143/DC1.
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